BioInvent presents promising new clinical and preclinical data on anti-FcγRllB antibody, BI-1206, at the ASH Annual Meeting

4. November 2020 INDIZES WEUR

– Signs of efficacy as first responses observed in lymphoma patients who have relapsed after treatment with rituximab- Preclinical data further …
(Orginal – Story lesen…)

Tags: atx cac ftse ibex omxs wig-20

You may also like...